Vetoquinol SA
Closed
SectorHealthcare
75.2
Overview
Share price change
24h
Min
73.7
Max
76.5
Income | -1.8M 31M |
|---|---|
Sales | -8.8M 259M |
P/E Sector Avg | 13.713 55.725 |
Dividend yield | 1.26 |
Profit margin | 11.762 |
Employees | 2,526 |
EBITDA | -245M 56M |
Dividend yield Sector Avg | 1.26% 2.25% |
|---|
Market Cap | 81M 867M |
|---|---|
Previous open | 75.2 |
Previous close | 75.2 |
News Sentiment
By Acuity
50%
50%
119 / 339 Ranking in Healthcare
Vetoquinol SA Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Vetoquinol SA Forecast
Sentiment
By Acuity
119 / 339 Ranking in Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.